TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]
Continue reading …
Turalio FDA approval : Daiichi Sankyo has secured approval for its CSF1R inhibitor Turalio (pexidartinib) from the US Food and Drug Administration (FDA) for the treatment of tenosynovial giant cell tumor (TGCT). The FDA approval of Turalio is for the treatment of adult patients having symptomatic tenosynovial giant cell tumor associated with severe morbidity or […]
Continue reading …
Darolutamide FDA approval : German pharma giant Bayer and Finnish pharma company Orion have secured approval from the US Food and Drug Administration (FDA) for their non-steroidal androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of men having non-metastatic castration-resistant prostate cancer (nmCRPC). The FDA approval of darolutamide was driven on the findings of […]
Continue reading …MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer
July 31, 2019 No Comment
MONARCH 2 clinical trial results : Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant delivered a statistically significant improvement in overall survival in the phase 3 MONARCH 2 clinical trial held for a type of metastatic breast cancer. The US pharma giant said that the MONARCH 2 clinical trial results […]
Continue reading …
Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as per the latest pharma acquisition news. AMAL Therapeutics, which was spun out from the University of Geneva in 2012, is focused on cancer immunotherapy and is engaged in advancing therapeutic […]
Continue reading …
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]
Continue reading …
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]
Continue reading …
Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 for the treatment of non-muscle invasive bladder cancer (NMIBC). The development comes following the conclusion of a 30-day review of the investigational new drug application (IND) of VAX014 by the […]
Continue reading …
X4 Pharmaceuticals has completed its previously announced merger with Arsanis in a move to create a late-stage biopharma company focused on rare diseases and cancer. Both companies are based in Massachusetts. X4 Pharmaceuticals is engaged in developing drugs designed to boost immune cell trafficking for the treatment of rare diseases that include primary immunodeficiencies and […]
Continue reading …Bexion Pharmaceuticals launches phase 1 part 3 trial of cancer drug BXQ-350
February 24, 2019 No Comment
US pharma company Bexion Pharmaceuticals has launched part 3 of their phase 1 human trial for BXQ-350 for cancer treatment. The early stage trial is aimed at determining the maximum tolerated dose of BXQ-350 and to characterize the safety and pharmacokinetics of the investigational cancer drug. The part 1 of the phase 1 trial saw […]
Continue reading …
Business News Today
- Coronavirus outbreak : Natural Grocers implements early store closures
- Provident Financial Services, SB One Bancorp sign $209m merger deal
- Banco Santander acquires 50.1% stake in Spanish fintech company Mercury TFS
- Rapid coronavirus test developed by Chicago-based Surgisphere
- World Insurance Associates acquires Virginia Insurance Partners
- Martin Linge field : Equinor reports novel coronavirus case on offshore platform
- Amethis takes minority stake in Kenyan supermarket chain Naivas
- Boston Omaha acquires rural broadband provider AireBeam Communications
- FDA approves Opdivo + Yervoy for HCC previously treated with sorafenib
- Jacob Leinenkugel launches seltzer beer brand Leinenkugel’s Spritzen
